Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up

Glaxosmithkline Share Price (GSK)

Show Chart Filters
Time period:
Moving Average:
Compare to:
Price 1,555.20on 07-08-2020 at 16:30:00
Change 5.20 0.34%
Buy 1,554.20
Sell 1,553.40
Buy / Sell GSK Shares
Sponsored Financial Content
Last Trade: Buy 44,750 at 1,554.861p
Day's Volume: 4,233,110
Last Close: 1,550.00p
Open: 1,557.00p
ISIN: GB0009252882
Day's Range 1,546.20p - 1,564.40p
52wk Range: 1,328.60p - 1,857.00p
Market Capitalisation: £78,030m
VWAP: 0.00p
Shares in Issue: 5,017m

Recent Trades History Glaxosmithkline (GSK)

Buy/Sell Volume Trade Prc Trade Type Trade Time
Buy*44,7501,554.861Ordinary
19:02:17 - 07-Aug-20
Buy*79,4901,555.20Ordinary
Delayed publication
17:15:38 - 07-Aug-20
Buy*41,1971,558.638Ordinary
Delayed publication
16:59:53 - 07-Aug-20
Buy*85,3611,555.20Ordinary
Delayed publication
17:15:33 - 07-Aug-20
Sell*235,4371,542.804Ordinary
Delayed publication
17:56:32 - 07-Aug-20
Buy*1001,554.958Ordinary
17:49:53 - 07-Aug-20
Buy*129,1051,555.146Ordinary
17:21:58 - 07-Aug-20
Buy*11,1321,556.072Ordinary
17:21:57 - 07-Aug-20
Buy*1,7691,555.048Ordinary
17:20:27 - 07-Aug-20
Buy*61,1201,554.861Ordinary
17:16:49 - 07-Aug-20

Share Price History for Glaxosmithkline

Time period:
to
Date Open High Low Close
6th Aug 2020 (Thu)1,567.001,571.201,540.401,549.10
5th Aug 2020 (Wed)1,585.201,592.201,563.201,565.00
4th Aug 2020 (Tue)1,575.601,587.201,560.201,571.80
3rd Aug 2020 (Mon)1,533.201,588.401,530.201,588.20
31st Jul 2020 (Fri)1,515.001,554.401,515.001,535.00
30th Jul 2020 (Thu)1,555.801,567.401,521.201,548.70
29th Jul 2020 (Wed)1,589.401,631.601,546.201,548.70
28th Jul 2020 (Tue)1,587.801,608.601,582.801,606.10
27th Jul 2020 (Mon)1,574.801,588.001,569.401,583.80
24th Jul 2020 (Fri)1,575.401,589.601,567.001,576.60
23rd Jul 2020 (Thu)1,608.401,627.601,600.001,605.50
22nd Jul 2020 (Wed)1,623.001,630.001,604.801,610.70
21st Jul 2020 (Tue)1,641.001,652.801,618.601,624.10
20th Jul 2020 (Mon)1,650.001,669.801,628.001,661.50
17th Jul 2020 (Fri)1,639.801,664.201,629.201,661.50
16th Jul 2020 (Thu)1,647.801,655.601,630.001,631.20
15th Jul 2020 (Wed)1,628.601,656.201,620.401,654.50
14th Jul 2020 (Tue)1,594.001,616.201,585.201,601.80
13th Jul 2020 (Mon)1,580.201,602.401,573.001,601.80
10th Jul 2020 (Fri)1,583.801,594.801,567.801,573.50
9th Jul 2020 (Thu)1,611.401,619.001,590.201,594.60
8th Jul 2020 (Wed)1,609.201,628.001,601.001,607.50

GSK - Glaxosmithkline Investor Summary

GlaxoSmithKline, or 'GSK', is one of the world's leading pharmaceutical companies researching medicines and vacines alike for the World Health Organization's three priority diseases: HIV/AIDS, Malaria and Tuberculosis. With an estimated 7% of the world's pharmaceutical market under its wing, GSK remains one of the industry leaders globally but remains committed to the research and application of life changing and marketable drugs.

If investing in science seems a little confusing and unpredictable then perhaps some of GSK's over-the-counter and more recognisable products will help to convince; these include Gaviscon and Panadol, smoking control products such as Nicorette/Niquitin and nutritional healthcare drinks such as Lucozade, Ribena and Horlicks.

On 23rd January 2009, GSK announced that it had signed an agreement with UCB S.A to acquire its marketed product portfolio in certain parts of the Middle East, Africa, Latin America and Asia Pacific, for a cash consideration of some £484 million. President of Emerging Markets at GSK, Abbas Hussain, said that "This acquisition will strengthen and expand GSK's product portfolio in these countries, helping us to meet the needs of patients, particularly in the areas of epilepsy and respiratory." Under the agreement, GSK acquires several leading pharmaceutical brands and investors will be interested to know that the commercial operations and product distribution rights included represent approximately 3-4% of UCB's 2008 expected revenue of at least £3.09 billion. At the time of Mr Hussain speaking, share prices for GSK were steady at 1,226.00p with a "strong buy" recommendation from brokers.

News about Glaxosmithkline (GSK)

GlaxoSmithKline blood cancer treatment gets US regulatory nod

News - Thursday, August 06, 2020

Pharmaceutical company GlaxoSmithKline said the US Food and Drug Administration ......

FTSE 100 heads higher into lunchtime despite heavy HSBC losses

News - Monday, August 03, 2020

UK stocks reversed opening softness to put in a late morning surge on Monday as ......

FTSE 100 Latest
Value6,032.18
Change5.24


Login to your account

Forgot Password?

Not Registered